Study of the Safety, Tolerability and Efficacy of the Investigational Anti PD-L1 Monoclonal Antibody Durvalumab in Combination With Paclitaxel in Patients With Metastatic Triple Negative PD-L1 Positive Breast Cancer
Phase of Trial: Phase I/II
Latest Information Update: 15 Dec 2016
At a glance
- Drugs Durvalumab (Primary) ; Paclitaxel (Primary)
- Indications Breast cancer
- Focus Adverse reactions
- 12 Dec 2016 Status changed from active, no longer recruiting to recruiting.
- 17 Oct 2016 Planned End Date changed from 1 Jan 2018 to 1 Jun 2018.
- 17 Oct 2016 Planned primary completion date changed from 1 Jun 2017 to 1 Dec 2017.